Skip to main content
An official website of the United States government
Email

Pediatric Immunotherapy Network (PIN)

A killer T cell (blue) engaging a target cell, with cell-killing molecules (red) traveling along the target cell's cytoskeleton (green).

A killer T cell (blue) engaging a target cell, with cell-killing molecules (red) traveling along the target cell's cytoskeleton (green).

Credit: National Institutes of Health

The Pediatric Immunotherapy Network (PIN) is an initiative (supported by DCB and the NCI Division of Cancer Treatment and Diagnosis (DCTD) through RFA-CA-22-016) that aims to address current challenges in pediatric immuno-oncology and accelerate the development of effective immunotherapies for pediatric solid tumors.

PIN research projects are focusing on mechanisms of immune evasion in childhood cancers, the development of preclinical models for pediatric immuno-oncology, the discovery and validation of novel immunotherapeutic targets in pediatric tumors, and the design of new pediatric immunotherapy agents and treatment approaches.

The overall goal of PIN is to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors (including brain cancers). 
 

PIN News

Recent Administrative Supplements for Collaborative Research

Dr. John Maris, a PIN investigator, is collaborating with Dr. Drew Weissman (University of Pennsylvania RNA Innovation Institute) to develop mRNA-based nanoparticle vaccines to treat neuroblastoma.

Dr. Vandana Kalia, a PIN investigator, is working with Dr. Surojit Sarkar (Seattle Children's Hospital) to  study how regulatory T cells affect responses to immunotherapy with bispecific T cell engagers.

Contacts for PIN

For additional information about PIN, please contact Dr. Yin Liu and Dr. Lillian Kuo in DCB or Dr. Anju Singh and Dr. Marco Cardone in DCTD. 

Funded Projects

Institution Principal Investigator(s) Project Title
St. Jude Children's Research Hospital Hongbo Chi, Jiyang Yu Enabling Immunotherapy for High-Risk Group 3 Medulloblastoma via Systems Immunology
St. Jude Children's Research Hospital Stephen C. Mack, Giedre Krenciute, Timothy N. Phoenix Targeting Tumor and T Cell DNA Methylomes to Improve CAR T Cell Therapies for Diffuse Midline Glioma
Stanford Crystal Mackall, Sabine Heitzeneder Attacking the Immunopeptidome of Ewing Sarcoma
Dana-Farber Cancer Institute Robbie G. Majzner, Kimberly Stegmaier Immunotherapeutic Targeting of Gangliosides in Ewing Sarcoma
Children's Hospital of Philadelphia  John M. Maris, Stephen P. Schoenberger Personalized Neuroblastoma Vaccines
Seattle Children's Hospital  James M. Olson, Vandana Kalia Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Pediatric Immunotherapy Network (PIN) was originally published by the National Cancer Institute.”

Email